{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-126579","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.659526+00:00","generated_at":"2026-05-15T08:50:16.156455+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LeonaBio reports FY2025 net loss $105.6M; acquires Phase 3 lasofoxifene, raises $90M","bullets":["Net loss of $105.6M ($24.70 per share) for FY2025 vs $96.9M loss in FY2024; R&D expenses rose to $85.6M on lasofoxifene license costs.","Cash and investments $88.3M at Dec 31, 2025, up from $51.3M year-end 2024; $90M private placement closed with potential $146M from warrant exercises.","Exclusive global license acquired for Phase 3 lasofoxifene (SERM) for ESR1-mutated metastatic breast cancer; ELAINE-3 enrollment completion expected 4Q2026, topline data 2H2027.","ATH-1105 Phase 2 proof-of-concept trial in ALS patients on track to initiate in 2H2026; Phase 1 data showed favorable safety and CNS penetration.","G&A expenses decreased to $16.7M from $26.1M, reflecting cost efficiencies; company renamed from Athira to LeonaBio in Jan 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-126579","json":"https://secwatch.observer/filing/0001193125-26-126579.json","markdown":"https://secwatch.observer/filing/0001193125-26-126579.md","text":"https://secwatch.observer/filing/0001193125-26-126579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526126579/0001193125-26-126579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526126579/lona-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:50:16.156455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cafbd0202d773a5987af415c0ca93f934e79237b","claim":"LeonaBio, Inc. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"On March 26, 2025, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526126579/0001193125-26-126579-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}